Takeda and AC Immune have entered an exclusive global licensing agreement for AC Immune's Alzheimer's treatment, ACI-24.060. The treatment targets toxic forms of amyloid beta, stimulating an antibody response that inhibits plaque formation in the brain to treat Alzheimer's disease.

As per the agreement, AC Immune will receive an upfront payment of USD 100 million, approximately USD 2.1 billion in development, commercial, and sales-related milestone payments, and tiered double-digit royalties on worldwide net sales after the commercialization of the product. 

AC Immune is a Switzerland-based biopharmaceutical company specializing in developing therapeutic and diagnostic products aimed at neurodegenerative diseases, often linked to protein misfolding. The company uses two proprietary technology platforms, SupraAntigen and Morphomer, to develop biologics, small molecules, and vaccines. AC Immune’s key drug candidates include Crenezumab, designed to slow the progression of Alzheimer's disease, and Semorinemab, targeting Tau proteins in Alzheimer's patients​.